Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus NALLPEN.
LAROTID vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic